Competitor Analysis: Targeted Therapy of Obesity

Publisher: La Merie Publishing
Pages: 80
Format: PDF
Product Line:
Competitor Analysis
Version: Download file
Product Code: LMCA0057
Release Date: March of 2011

500.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Targeted Therapy of Obesity

Product description

The present Competitive Intelligence Report about Targeted Therapy of Obesity provides a competitor evaluation in the field of novel molecules being developed for treatment of obesity as of March 2011. Pharmacologic approaches include reduction of energy uptake from the GI and Genitourinary tract, reduction of food consumption via peripheral mechanisms as well as via signalling to the brain from the GI tract, action in the CNS and reduction of fat mass & regulation of energy metabolism. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Obesity is a serious and worldwide health problem because it is a major risk factor for metabolic syndrome including pre-diabetes, hypertension and other cardiovascular (CV) and non-CV complications. Pharmacotherapeutic options so far are limited in their effect or even have been withdrawn from market due to neuropsychological side effects. Despite many study failure, the clinical pipeline consists of more than 43 different molecular entities with four drugs in pre-registration of registration phases. Molecular strategies in R&D include intentions to lower body weight or adipose tissue mass by reducing the absorption of lipids from the GI tract, to limit food intake, or to increase energy expenditure or to reduce adipose tissue size. The majority (74%) of the new molecular entities (NME) in development for treatment of obesity are small molecules, and about 18 % of the NMEs are anti-obesity peptides.

The report includes a compilation of currently active projects in clinical research and development of antisense, aptamer, LNA RNA, RNAi and CpG oligonucleotide therapeutics for treatment of a variety of clinical disorders. In addition, the report lists company-specific R&D pipelines of RNA Therapeutics in Clinical Develompent. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Index

1) Reduction of Energy Uptake from the GI and Genitourinary Tract
1a) Inhibitors of Panreatic Lipase
1b) Inhibitors of Intestinal Microsomal Trigliceride Transfer
Protein (MTP)
1c) Inhibitors of Acyl-CoA:diacyl-glycerol acyltransfe-rase 1
(DGAT1)
1d) Inhibitors of Low-Affinity Sodium-Dependent Glucose Co-
transporters (SGLT2)
1e) Others
2) Reduction of Food Consumption via Peripheral Mechanisms
2a) Cannabinoid 1 (CB1) receptor antagonist
2b) GPR119 agonists
2c) Opioid Receptors
2d) PPAR Agonists
2e) Antagonists of Glucocorticoid Receptor (GCCR)
2f) Others
3) Reduction of Food Consumption via Signalling to the Brain from the GI Tract
3a) Amylin & Leptin Analogues
3b) Peptide YY (PYY) & Pancreatic Polypeptide (PP) Analogues
3c) GLP-1 & Oxyntomodulin Analogues
3d) Cholecystokinin (CCK) Agonists
3e) Ghrelin Receptor Antagonists
3f) Others
4) Centrally Acting Drugs
4a) Compounds Predominantly Modulating Local Availability of
Dopamine, Norepinephrine and Serotonin in the Brain
4b) MC4R (Melanocortin 4 Receptor) Agonists and MCH-R1
(Melanin-Concentrating Hormone Receptor 1) Antagonists
4c) H3 Receptor Antagonists
4d) Neuropeptide Y (NPY) Receptor Antagonists & Agouti-
Related Protein (AgRP) Inhibitors
5) Reduction of Fat Mass & Regulation of Energy Metabolism
5a) Growth Hormone (GH) Analogues
5b) 11beta-Hydroxysteroid Dehydrogenase type 1 (11beta-
HSD1) Inhibitors
5c) Angiogenesis Inhibitors
5d) TGR5 Agonists
5e) Methionine aminopeptidase 2 (MetAP2) Inhibitors
5f) Other Metabolic Modifiers
6) Various Approaches
7) Unspecified Targets

• Corporate Targeted Therapy of Obesity R&D Pipelines

 

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top